Preliminary findings of Phase I/II dose-expansion study of DS-7300 (a B7-H3 antibody-drug conjugate) in mCRPC patients backed B7-H3 as a potential new target in treatment-resistant prostate cancers (Abstract #87)
Immune-checkpoint inhibitors (ICI) have resulted in significant therapeutic advancements in a wide range of tumor types, including melanoma, NSCLC, bladder, and kidney cancers, among others. However, ICI’s has produced moderate outcomes in advanced prostate cancer, which may be because prostate cancer cells do not express much PD-L1, and thus people with prostate cancer respond less strongly to these treatments. On the other hand, B7-H3 (CD276) has been sh...
